Executive Director, Global Medical Strategy Head - Gastrointestinal Cancers

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers.  The company’s R&D pipeline comprises of RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

The Executive Director, Global Medical Strategy Head (GMSH) Gastrointestinal (GI) Cancers is a key member of the Medical Affairs leadership team. This individual will be responsible for developing and executing the Global Medical Affairs (GMA) strategy and tactical plans with a focus on launch readiness and life cycle management for medicines across the current and future GI cancer portfolio. The successful candidate will have a proven track record of developing and driving medical strategy for multiple assets with a focus on effectively communicating key scientific data through publications, medical information, medical communications, and congress activities as well as gathering insights through Advisory Boards and Key Opinion Leader (KOL) engagements. He/she will be an experienced people manager who will lead and expand the GI cancer medical team while fostering inclusivity and developing talent. This leader must work collaboratively with cross-functional counterparts in Development, Research and Commercial as well as other partners in the organization to design and implement a comprehensive strategy across all GI cancer indications.

Key aspects of the GMSH role include the following: lead the development and execution of the multi-year global and US medical strategy for GI cancers, including oversight of the publication and medical communications strategy, integrated evidence planning, lifecycle management and budget and headcount planning process. This individual will be responsible for building and leading a GI cancer strategy team. As a senior member of the GMA team, the GMSH will also be expected to lead the Global Medical Affairs Team (GMAT) to execute medical strategies, contribute to the operations and oversight of medical activities associated with GI cancers, work cross-functionally to support associated pre-launch activities, provide regular updates and support to senior leadership.

The ideal candidate is a skilled and collaborative leader, highly effective communicator, entrepreneurial, detail-oriented, proactive, and scientifically driven.

• Serves as a member of the Global Medical Leadership Team contributing to overall medical portfolio management and prioritization as well as contributing to the development of the multi-year GMA strategic plan

• Lead the GI cancer team in the development and execution of the GMA strategy and medical objectives for the GI cancer franchise including activities related to scientific engagement and communication, evidence generation, internal education, and patient advocacy.

• Lead integrated evidence generation planning across GI cancers including conducting routine cross-functional gap assessments leading to the development/refinement of a publication strategy, an evidence generation plan, and a tactical plan as part of the overall GMA plan.

• Provide medical leadership in scientific engagement activities with key external stakeholders through organizing and leading advisory boards, study investigator interactions, congress activities, and peer-to-peer discussions with the goal of communicating scientific insights to internal teams to drive strategy.

• Serves as a senior medical leader communicating clinical and scientific data to physicians and other healthcare professionals through presentations, educational programs, and scientific discussions.

• Leads medical contribution to cross-functional strategy team meetings including Clinical and Safety sub-teams, product team, Market Access, commercial and other cross-functional strategic discussions.

• Work closely with the Clinical and MSL teams to provide enrollment, scientific, and engagement support to ensure clinical trials meet study timelines.

• Partner with RWE strategy and translational teams on related integrated evidence-generation strategies and activities as part of the GMA Plan.

• Partner with Patient Advocacy to incorporate the patient voice and define external medical education strategies for independent grants, respectively.

• Support competitive intelligence team activities through landscape assessments, development of patient journey, and congress insights

• Provide medical support for scientific symp